These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24901827)

  • 1. An Italian perspective: studying the cost-effectiveness of sofosbuvir before completion of national price negotiations.
    Messori A; Maratea D; Fadda V; Gatto R; Trippoli S
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):813-4. PubMed ID: 24901827
    [No Abstract]   [Full Text] [Related]  

  • 2. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The uses and abuses of cost-effectiveness analysis.
    Goozner M
    Mod Healthc; 2014 Aug; 44(32):26. PubMed ID: 25318245
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 5. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A national drug agency.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    CMAJ; 2003 Apr; 168(8):962-3. PubMed ID: 12695372
    [No Abstract]   [Full Text] [Related]  

  • 7. Implementing pharmacoeconomic guidelines in Latin America: lessons learned.
    Augustovski F; Melendez G; Lemgruber A; Drummond M
    Value Health; 2011; 14(5 Suppl 1):S3-7. PubMed ID: 21839895
    [No Abstract]   [Full Text] [Related]  

  • 8. China rejects patent on hepatitis C drug sofosbuvir.
    Kmietowicz Z
    BMJ; 2015 Jun; 350():h3429. PubMed ID: 26105994
    [No Abstract]   [Full Text] [Related]  

  • 9. Why Sovaldi shouldn't cost $84,000.
    Goozner M
    Mod Healthc; 2014 May; 44(18):26. PubMed ID: 25033627
    [No Abstract]   [Full Text] [Related]  

  • 10. Insurers brace for high-cost Sovaldi.
    Demko P; Dickson V
    Mod Healthc; 2014 May; 44(18):9. PubMed ID: 25033622
    [No Abstract]   [Full Text] [Related]  

  • 11. Dare to refuse the exorbitant price of Sovaldi!
    Prescrire Int; 2014 Nov; 23(154):278. PubMed ID: 25954802
    [No Abstract]   [Full Text] [Related]  

  • 12. Campaigners challenge patent applications for hepatitis C drug in five countries.
    Bagcchi S
    BMJ; 2015 Jun; 350():h2938. PubMed ID: 26032985
    [No Abstract]   [Full Text] [Related]  

  • 13. [May drugs be a cost-effective investment in Spanish health system?].
    Soto J; Olivella P
    Med Clin (Barc); 2001 Nov; 117(16):622-4. PubMed ID: 11714470
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The drug budget silo mentality in Europe: an overview.
    Garrison L; Towse A
    Value Health; 2003; 6 Suppl 1():S1-9. PubMed ID: 12846921
    [No Abstract]   [Full Text] [Related]  

  • 16. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies.
    Hailey D
    Soc Sci Med; 1997 Aug; 45(4):563-81. PubMed ID: 9226782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluating the effectiveness of drugs. "The full potential of a therapy is often only clear after a number of years" (interview by Helmut Laschet)].
    Pfundner H
    MMW Fortschr Med; 2010 Dec; 152(51-52):10. PubMed ID: 21294362
    [No Abstract]   [Full Text] [Related]  

  • 18. A prescription for change.
    Testoni M
    Healthc Financ Manage; 2015 Oct; 69(10):30, 32. PubMed ID: 26595972
    [No Abstract]   [Full Text] [Related]  

  • 19. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value based pricing: can it work?
    Raftery J
    BMJ; 2013 Oct; 347():f5941. PubMed ID: 24124158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.